Resources
About Us
Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User - Forecast to 2030
Report ID: MRHC - 104869 Pages: 150 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours Download Free Sample ReportThe Europe Single-use Bioreactors Market is projected to reach $3.34 billion by 2030, at a CAGR of 15.3% from 2024 to 2030. Single-use bioreactors, also called disposable bioreactors, are made of disposable bags instead of a culture vessel. These bioreactors eliminate the need for expensive and bulky clean-in-place (CIP) or steam-in-place (SIP) systems and offer flexibility and a low risk of contamination, contributing to their adoption by pharma & biotech companies. Along with this, end users' manufacturing and R&D capacity expansion increases the demand for the products in the region. For instance, in September 2022, Viralgen Vector Core (Viralgen), a member of the Bayer worldwide group of companies, received Certified Good Manufacturing Practices (cGMP) certification for human medicinal products, investigational medicinal products, and sterile or biologically active substances.
The rapid adoption of disposable technology in the pharmaceutical and biotechnology industry, growing demand for biopharmaceuticals, government support for the production & use of biopharma products for various health indications, and capacity expansion of biopharmaceutical plants are some of the major factors driving the growth of the Europe single-use bioreactors market.
Rising demand for biologicals and biosimilars; the rising cost of drug development; the growing demand for cell therapies, gene therapies, and personalized medicines; and the growing consolidation among CDMOs & CROs supported the adoption of single-use bioreactors for end users in the region.
CDMOs support pharmaceutical & biotechnology firms through outsourced research and manufacturing services on a contractual basis. Pharmaceutical and biopharmaceutical companies depend on CDMOs to reduce R&D efforts, avoid the high fixed costs of in-house development, and harness the manufacturing capabilities and expertise required to drive their molecules through clinical development. These organizations offer a broad range of services in preclinical research, clinical research, assay development, clinical trial management, and bioproduction.
Pharmaceutical & biopharmaceutical companies are increasingly adopting drug discovery outsourcing to reduce the overall drug development time & related costs, improve R&D productivity, optimize operational flexibilities, and increase their profit margins. Looking at the growing market of CDMOs, various key players in the life science industry are taking steps toward acquiring CDMOs. In May 2024, eureKING (France) acquired Skyepharma (CDMO) (France) to build biotherapies segments and expand its biomanufacturing capacity. The acquisitions of CDMOs by large companies lead to the expansion of the capacities of CDMOs, which in turn is beneficial for the single-use bioreactors market. Also, the expansion by CDMOs for biomanufacturing supports the growth of this segment. For instance,
Thus, such expansion increases demand for biopharma products, thereby driving the Europe single-use bioreactors market for these end users.
Click here to: Get a Free Sample Copy of this Report
Government Initiatives to Increase Bioproduction is an Opportunity for the Players in this Market
European governments are investing in the pharma & biopharma industry to boost R&D and bioproduction. The government and other public groups and enterprises are providing funding and grants for research and development to pharmaceutical, biopharmaceutical, and biotech companies, thereby helping to grow the biopharmaceutical market and increasing demand for single-use bioreactors. For instance,
Among Products, the Media Bags Segment is Projected to Register the Highest CAGR
Advantages like high flexibility, low levels of extractable and leachable and high product stability during storage compared to culture vessels supported the market growth. Also, the low risk of cross-contamination from batch to batch and product to product and eliminating the time and expense of sterilization-in-place (SIP) & clean-in-place (CIP) operations, optimizing capacity utilization, increase their adoption for bioprocessing.
Among Types, the Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR
Wave-induced bioreactor systems offer various benefits, like no need to rely on oxygen bubbles for culture aeration, generation of rocking motion to meet the required amount of oxygen for cell growth, and a large surface-to-volume ratio. These benefits lead to driving the market at the highest growth rate.
In contrast to conventional stirred tank bioreactors, wave-induced bioreactor systems improve fluid turnover and minimize shear forces compared to stirred tanks. Such flow conditions reportedly produce better cell suspension and reduce the risk of cell damage and thus have enabled rocking-motion bioreactors to reach higher maximum cell densities than traditional spinner flasks.
Among Cell Types, in 2024, the Mammalian Cells Segment is Expected to Account for the Largest Share
In 2024, the mammalian cells segment is expected to account for the largest share of the market. Increased need for mAbs production with consistent quality and preference for culturing in large-scale suspension bioreactors to increase bioproduction supported the share. Also, Demand for high throughput operations in cell culture processing will continue to drive the single-use bioreactor market for mammalian cells.
The Research Bio-production Segment is Projected to Register the Highest CAGR
Among the application, the research bio-production segment is projected to register the highest CAGR owing to growing support from regulatory agencies & companies’ initiatives. For instance, in January 2021, the Circa Group Europe Limited (Ireland) invested USD 2.2 billion (EUR 2 billion) in biopharmaceutical research and development through IDA Ireland’s client companies annually. Thus, such an investment plan helps boost the demand for biopharma products in the European region, thereby driving the market.
Among End Users, in 2024, the Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment is attributed to the rise in R&D activities, the focus of U.S.-based companies to expand their manufacturing capacities in European countries, the high adoption of bioreactors in pharmaceutical laboratories, and concerns over flexibility, sterility, cost efficiency, and enhanced productivity.
Also, increasing demand for biopharmaceutical products, growing adoption of single-use products, growing incidence & prevalence of various chronic diseases, rising R&D expenditure by pharmaceutical & biotechnology companies, and recent launches of biologics for chronic & rare diseases raise the growth of the market for them.
Germany: In 2024, to Account for the Largest Share of the Market
The factors supporting the large share of this market include increasing pharmaceutical export, government grants, growth in immunization, and funding to biotech & biopharmaceutical companies expanding their capacities for biologics to meet the market's increasing demand. Being one of the largest biopharma markets in the EU region and the presence of key players in the country supported their large share in the market.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants in the last 3 to 4 years. The key players profiled in the Europe single-use bioreactors market report are Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.) CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).
Scope of the Report:
Europe Single-use Bioreactors Market, by Product
Europe Single-use Bioreactors Market, by Type
Europe Single-use Bioreactors Market, by Cell Type
Europe Single-use Bioreactors Market, by Application
Europe Single-use Bioreactors Market, by End User
Europe Single-use Bioreactors Market, by Country
Key questions answered in the report:
This study offers a detailed assessment of the Europe single-use bioreactors market, including the market size & forecast for various segmentations, including product, type, cell type, application, and end user. The Europe single-use bioreactors market studied in this report also involves the value analysis of various segments and sub-segments of single-use bioreactors at country levels.
The Europe single-use bioreactors market is projected to reach $3.34 billion by 2030, at a CAGR of 15.3% during the forecast period.
Among the product, in 2024, the single-use bioreactor systems segment is expected to account for the largest share of the single-use bioreactors market.
Among the type, the wave-induced bioreactors segment is projected to register the highest CAGR over the forecast period. The advantages offered by these bioreactors over stirred-tank and increasing cell-based research supported the adoption are the key factors supporting market growth.
The growth of this market is driven by the increasing sales of drugs and support from government & regulatory authorities to promote the use of biopharmaceuticals for health indications. Various companies expanding their manufacturing capacities and operations offer significant opportunities for the players operating in this market.
The key players profiled in the Europe single-use bioreactors market report are Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.) CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).
Germany and France are projected to offer significant growth opportunities to the market players due to government initiatives to promote biosimilars, increasing healthcare expenditure, and growing investment in biopharmaceutical companies to expand their operations and manufacturing capacities.
Published Date: Jul-2024
Published Date: Apr-2024
Published Date: May-2023
Published Date: Jul-2024
Published Date: Dec-2022
Please enter corporate email id here & we’ll send you a free sample.
Subscribe to get the latest industry updates